Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn’s disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study
Mirikizumab was safe and effective as induction and maintenance treatment for patients with moderately-to-severely active Crohn’s disease who had intolerance, inadequate response, or loss of response to standard therapy.